-
1
-
-
0036727151
-
Bisphosphonate mechanism of action
-
Rodan GA, Reszka AA. Bisphosphonate mechanism of action. Curr Mol Med 2002;2:571-7.
-
(2002)
Curr Mol Med
, vol.2
, pp. 571-7
-
-
Rodan, G.A.1
Reszka, A.A.2
-
2
-
-
33747888167
-
Osteoporosis, bisfosfonatos y calcitonina
-
Mellibovsky L. Osteoporosis, bisfosfonatos y calcitonina. JANO 2001;61:47-54.
-
(2001)
JANO
, vol.61
, pp. 47-54
-
-
Mellibovsky, L.1
-
3
-
-
0032468984
-
Bisphosphonates: Mechanisms of action
-
Fleish H. Bisphosphonates: Mechanisms of Action. Endocr Rev 1998;19:80-100.
-
(1998)
Endocr Rev
, vol.19
, pp. 80-100
-
-
Fleish, H.1
-
4
-
-
0036148405
-
The role of bisphosphonates in breast cancer: Development of bisphosphonates
-
Fleish H. The role of bisphosphonates in breast cancer: Development of bisphosphonates. Breast Cancer Res 2002;4:30-4.
-
(2002)
Breast Cancer Res
, vol.4
, pp. 30-4
-
-
Fleish, H.1
-
5
-
-
0015939609
-
The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals
-
Jung, A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates on hydroxyapatite crystals. Calcif Tissue Res 1973;11:269-80.
-
(1973)
Calcif Tissue Res
, vol.11
, pp. 269-80
-
-
Jung, A.1
Bisaz, S.2
Fleisch, H.3
-
6
-
-
0020687209
-
Structureactivity relationships of various bisphosphonates
-
Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structureactivity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87-99.
-
(1983)
Calcif Tissue Int
, vol.35
, pp. 87-99
-
-
Shinoda, H.1
Adamek, G.2
Felix, R.3
Fleisch, H.4
Schenk, R.5
Hagan, P.6
-
7
-
-
0026694920
-
Retention of etidronate in human, dog, and rat
-
Kasting GB, Francis MD. Retention of etidronate in human, dog, and rat. J Bone Miner Res 1992;7:513-22.
-
(1992)
J Bone Miner Res
, vol.7
, pp. 513-22
-
-
Kasting, G.B.1
Francis, M.D.2
-
8
-
-
0030766092
-
Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis
-
Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, et al. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997;12:1700-7.
-
(1997)
J Bone Miner Res
, vol.12
, pp. 1700-7
-
-
Khan, S.A.1
Kanis, J.A.2
Vasikaran, S.3
Kline, W.F.4
Matuszewski, B.K.5
McCloskey, E.V.6
-
9
-
-
0026329441
-
Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone
-
Flanagan AM, Chambers TJ. Inhibition of bone resorption by bisphosphonates: Interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 1991;49:407-15.
-
(1991)
Calcif Tissue Int
, vol.49
, pp. 407-15
-
-
Flanagan, A.M.1
Chambers, T.J.2
-
10
-
-
0029133135
-
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
-
Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Toodman GD, et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995;10:1478-87.
-
(1995)
J Bone Miner Res
, vol.10
, pp. 1478-87
-
-
Hughes, D.E.1
Wright, K.R.2
Uy, H.L.3
Sasaki, A.4
Yoneda, T.5
Toodman, G.D.6
-
11
-
-
0022553220
-
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix
-
Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
-
(1986)
Bone Miner
, vol.1
, pp. 27-39
-
-
Boonekamp, P.M.1
Van Der Wee-Pals, L.J.2
Van Wijk-van Lennep, M.M.3
Thesing, C.W.4
Bijvoet, O.L.M.5
-
12
-
-
0027193759
-
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts
-
Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-11.
-
(1993)
J Clin Invest
, vol.91
, pp. 2004-11
-
-
Sahni, M.1
Guenther, H.L.2
Fleisch, H.3
Collin, P.4
Martin, T.J.5
-
13
-
-
0035460134
-
The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis
-
Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: Evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum 2001;44:2201-10.
-
(2001)
Arthritis Rheum
, vol.44
, pp. 2201-10
-
-
Frith, J.C.1
Monkkonen, J.2
Auriola, S.3
Monkkonen, H.4
Rogers, M.J.5
-
14
-
-
0027436434
-
Vivo Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents
-
Ciosek CP, Magnin DR, Harrity TW, Logan JV, Dickson JK, Gordon EM, et al. In vivo Lipophilic 1, 1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents. J Biol Chem 1993;268:24832-7.
-
(1993)
J Biol Chem
, vol.268
, pp. 24832-7
-
-
Ciosek, C.P.1
Magnin, D.R.2
Harrity, T.W.3
Logan, J.V.4
Dickson, J.K.5
Gordon, E.M.6
-
15
-
-
0034520352
-
Vivo effects of bisphosphonates on the osteoclast mevalonate pathway
-
Fisher JE, Rodan GA, Reszka AA. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000;141:4793-6.
-
(2000)
Endocrinology
, vol.141
, pp. 4793-6
-
-
Fisher, J.E.1
Rodan, G.A.2
Reszka, A.A.3
-
16
-
-
0031754521
-
Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
-
Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MG. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-78.
-
(1998)
J Bone Miner Res
, vol.13
, pp. 1668-78
-
-
Luckman, S.P.1
Coxon, F.P.2
Ebetino, F.H.3
Russell, R.G.G.4
Rogers, M.G.5
-
17
-
-
0031977199
-
Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including ras
-
Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MG. Nitrogencontaining bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of gtp-binding proteins, including ras. J Bone Miner Res 1998;13:581-9.
-
(1998)
J Bone Miner Res
, vol.13
, pp. 581-9
-
-
Luckman, S.P.1
Hughes, D.E.2
Coxon, F.P.3
Russell, R.G.G.4
Rogers, M.G.5
-
18
-
-
0033554651
-
Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
-
Van Beek E, Pieterman E, Cohen L, Löwik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11.
-
(1999)
Biochem Biophys Res Commun
, vol.264
, pp. 108-11
-
-
Van Beek, E.1
Pieterman, E.2
Cohen, L.3
Löwik, C.4
Papapoulos, S.5
-
19
-
-
0033958778
-
Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
-
Bergstrom JD, Bostedor RG, Masarachia PJ, Rewszka AA, Rodan GA. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000;373:231-41.
-
(2000)
Arch Biochem Biophys
, vol.373
, pp. 231-41
-
-
Bergstrom, J.D.1
Bostedor, R.G.2
Masarachia, P.J.3
Rewszka, A.A.4
Rodan, G.A.5
-
20
-
-
0031036965
-
Bisphosphonates: Preclinical aspects and use in osteoporosis
-
Fleish HA. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 1997;29:55-62.
-
(1997)
Ann Med
, vol.29
, pp. 55-62
-
-
Fleish, H.A.1
-
21
-
-
0037112368
-
Bisphosphonates inhibit angiogenesis in vitro and testosteronastimulated vascular regrowth in the ventral prostate in castrated rats
-
Fournier P, Boissier S, Filleur S, Guglielmi J, Cabon F, Colombel M, et al. Bisphosphonates inhibit angiogenesis in vitro and testosteronastimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538-44.
-
(2002)
Cancer Res
, vol.62
, pp. 6538-44
-
-
Fournier, P.1
Boissier, S.2
Filleur, S.3
Guglielmi, J.4
Cabon, F.5
Colombel, M.6
-
22
-
-
0036062211
-
Pharmacologic profile of zoledronic acid;a highly potent inhibitor of bone resorption
-
Green JR, Rogers MJ. Pharmacologic profile of zoledronic acid;a highly potent inhibitor of bone resorption. Drug Rev Res 2002;55:210-44.
-
(2002)
Drug Rev Res
, vol.55
, pp. 210-44
-
-
Green, J.R.1
Rogers, M.J.2
-
23
-
-
27844555334
-
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
-
Lenz JH, Steiner-Krammer B, Schmidt W, Fietkau R, Mueller PC, Gundlach KK. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Cranio- Maxillofac Surg 2005;33:395-403.
-
(2005)
J Cranio- Maxillofac Surg
, vol.33
, pp. 395-403
-
-
Lenz, J.H.1
Steiner-Krammer, B.2
Schmidt, W.3
Fietkau, R.4
Mueller, P.C.5
Gundlach, K.K.6
-
24
-
-
0041331740
-
Alendronate has a residual effect on bone mass in postmenopausal danish women up to 7 years after treatment withdrawal
-
Bagger YZ, Tanko LB, Alexandersen P, Ravn P, Christiansen C. Alendronate has a residual effect on bone mass in postmenopausal danish women up to 7 years after treatment withdrawal. Bone 2003;33:301-7.
-
(2003)
Bone
, vol.33
, pp. 301-7
-
-
Bagger, Y.Z.1
Tanko, L.B.2
Alexandersen, P.3
Ravn, P.4
Christiansen, C.5
-
25
-
-
24044431619
-
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease
-
Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005;353:898-908.
-
(2005)
N Engl J Med
, vol.353
, pp. 898-908
-
-
Reid, I.R.1
Miller, P.2
Lyles, K.3
Fraser, W.4
Brown, J.P.5
Saidi, Y.6
-
26
-
-
9044219839
-
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
-
Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996;334:488-93.
-
(1996)
N Engl J Med
, vol.334
, pp. 488-93
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
Dimopoulos, M.A.4
Bordoni, R.5
George, S.6
-
27
-
-
0036777368
-
The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs
-
Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 2002;75:249-58.
-
(2002)
Breast Cancer Res Treat
, vol.75
, pp. 249-58
-
-
Michigami, T.1
Hiraga, T.2
Williams, P.J.3
Niewolna, M.4
Nishimura, R.5
Mundy, G.R.6
-
28
-
-
13844297617
-
Ibandronate in metastatic bone disease: A review of preclinical data
-
Bauss F, Body JJ. Ibandronate in metastatic bone disease: A review of preclinical data. Anticancer Drugs 2005;16:107-8.
-
(2005)
Anticancer Drugs
, vol.16
, pp. 107-8
-
-
Bauss, F.1
Body, J.J.2
-
29
-
-
0035312469
-
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
-
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-200.
-
(2001)
Cancer
, vol.91
, pp. 1191-200
-
-
Berenson, J.R.1
Rosen, L.S.2
Howell, A.3
Porter, L.4
Coleman, R.E.5
Morley, W.6
-
30
-
-
4644261592
-
Mechanisms of bone metastasis
-
Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
-
(2004)
N Engl J Med
, vol.350
, pp. 1655-64
-
-
Roodman, G.D.1
-
34
-
-
0037309091
-
Scleritis and other ocular side effects associated with pamidronate disodium
-
Fraunfelder FW, Fraunfelder FT, Jensvold B. Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 2003;135:219-22.
-
(2003)
Am J Ophthalmol
, vol.135
, pp. 219-22
-
-
Fraunfelder, F.W.1
Fraunfelder, F.T.2
Jensvold, B.3
-
35
-
-
14644439945
-
Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy
-
Durnian JM, Olujohungbe A, Kyle G. Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye 2005;19:221-2.
-
(2005)
Eye
, vol.19
, pp. 221-2
-
-
Durnian, J.M.1
Olujohungbe, A.2
Kyle, G.3
-
36
-
-
0015130762
-
The treatment of osteoporosis with disodium ethane-1-hydroxy-1, 1-diphosphonate
-
Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P. The treatment of osteoporosis with disodium ethane-1-hydroxy-1, 1-diphosphonate. J Lab Clin Med 1971;78:574-84.
-
(1971)
J Lab Clin Med
, vol.78
, pp. 574-84
-
-
Jowsey, J.1
Riggs, B.L.2
Kelly, P.J.3
Hoffman, D.L.4
Bordier, P.5
-
37
-
-
0021328378
-
Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease
-
Boyce BF, Smith L, Fogelman I, Johnston E, Ralston S, Boyle IT. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1984;1:821-4.
-
(1984)
Lancet
, vol.1
, pp. 821-4
-
-
Boyce, B.F.1
Smith, L.2
Fogelman, I.3
Johnston, E.4
Ralston, S.5
Boyle, I.T.6
-
40
-
-
0030093323
-
Symptomatic hypocalcaemia after intravenous pamidronate
-
McIntyre E, Bruera E. Symptomatic hypocalcaemia after intravenous pamidronate. J Palliat Care 1996;12:46-7.
-
(1996)
J Palliat Care
, vol.12
, pp. 46-7
-
-
McIntyre, E.1
Bruera, E.2
-
41
-
-
0035002570
-
Prolonged symptomatic hypocalcaemia with pamidronate administration and subclinical hypoparathyroidism
-
Mishra A, Wong L, Jonklaas J. Prolonged symptomatic hypocalcaemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine 2001;14:159-64.
-
(2001)
Endocrine
, vol.14
, pp. 159-64
-
-
Mishra, A.1
Wong, L.2
Jonklaas, J.3
-
42
-
-
0025965735
-
Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy
-
Fraser WD, Logue FC, Gallacher SJ, O'Reilly DS, Beastall GH, Ralston SH, et al. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Bone Miner 1991;12:113-21.
-
(1991)
Bone Miner
, vol.12
, pp. 113-21
-
-
Fraser, W.D.1
Logue, F.C.2
Gallacher, S.J.3
O'Reilly, D.S.4
Beastall, G.H.5
Ralston, S.H.6
-
43
-
-
0020696938
-
Renal failure associated with intravenous diphosphonates
-
Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F. Renal failure associated with intravenous diphosphonates. Lancet 1983;1:471.
-
(1983)
Lancet
, vol.1
, pp. 471
-
-
Bounameaux, H.M.1
Schifferli, J.2
Montani, J.P.3
Jung, A.4
Chatelanat, F.5
-
45
-
-
0030756221
-
Hypercalcemia of malignancy
-
Mundy GR, Guise TA. Hypercalcemia of malignancy. Am J Med 1997;103:134-45.
-
(1997)
Am J Med
, vol.103
, pp. 134-45
-
-
Mundy, G.R.1
Guise, T.A.2
-
46
-
-
29844444565
-
Alendronate and mouth ulcers: Careful interrogation of the patient to start with
-
Schmutz JL, Barbaud A, Trechot P. Alendronate and mouth ulcers: Careful interrogation of the patient to start with. Ann Dermatol Venereol 2005;132:930.
-
(2005)
Ann Dermatol Venereol
, vol.132
, pp. 930
-
-
Schmutz, J.L.1
Barbaud, A.2
Trechot, P.3
-
47
-
-
0042861578
-
Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
-
Marx RE. Pamidronate (Aredia) and zolendronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7.
-
(2003)
J Oral Maxillofac Surg
, vol.61
, pp. 1115-7
-
-
Marx, R.E.1
-
48
-
-
32644489792
-
Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: An update
-
Jiménez Y, Bagán JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: An update. Med Oral Patol Oral Cir Bucal 2005;10:88-91.
-
(2005)
Med Oral Patol Oral Cir Bucal
, vol.10
, pp. 88-91
-
-
Jiménez, Y.1
Bagán, J.V.2
-
49
-
-
12444268934
-
Avascular jaw osteonecrosis in association with cancer chemoterapy: Series of 10 cases
-
Bagán JV, Murillo J, Jiménez Y, Poveda R, Milian MA, Sanchos JM, et al. Avascular jaw osteonecrosis in association with cancer chemoterapy: Series of 10 cases. J Oral Pathol Med 2005;34:120-3.
-
(2005)
J Oral Pathol Med
, vol.34
, pp. 120-3
-
-
Bagán, J.V.1
Murillo, J.2
Jiménez, Y.3
Poveda, R.4
Milian, M.A.5
Sanchos, J.M.6
-
50
-
-
33646684262
-
Osteonecrosis maxilar y bisfosfonatos Presentación de tres nuevos casos
-
Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo- Pérez A, Sebatián-Lopez C. Osteonecrosis maxilar y bisfosfonatos. Presentación de tres nuevos casos. Med Oral Patol Oral Cir Bucal 2006;11:57-60.
-
(2006)
Med Oral Patol Oral Cir Bucal
, vol.11
, pp. 57-60
-
-
Pastor-Zuazaga, D.1
Garatea-Crelgo, J.2
Martino-Gorbea, R.3
Etayo- Pérez, A.4
Sebatián-Lopez, C.5
-
51
-
-
27344453813
-
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
-
Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
-
(2005)
J Oral Maxillofac Surg
, vol.63
, pp. 1567-75
-
-
Marx, R.E.1
Sawatari, Y.2
Fortin, M.3
Broumand, V.4
-
52
-
-
17644406724
-
Bisphosphonates and avascular necrosis of the jaw: A possible association
-
Carter G, Goss AN, Doecke C. Bisphosphonates and avascular necrosis of the jaw: A possible association. Med J Aust 2005;182:413-5.
-
(2005)
Med J Aust
, vol.182
, pp. 413-5
-
-
Carter, G.1
Goss, A.N.2
Doecke, C.3
-
53
-
-
0642316721
-
Bisphosphanates and oral cavity avascular bone necrosis
-
Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 2003;21:4253-4.
-
(2003)
J Clin Oncol
, vol.21
, pp. 4253-4
-
-
Migliorati, C.A.1
-
55
-
-
0003320840
-
PS-341(Bortazomib) is active in multiple myeloma Preliminary report of a phase I trial of the proteasome inhibitor PS- 341 in patients with hematologic malignancies
-
Stinchcombe TE, Mitchell BS, Depcets-Smith N, Orlowski RZ, Shea TC, Baldwin AS et al. PS-341(Bortazomib) is active in multiple myeloma. Preliminary report of a phase I trial of the proteasome inhibitor PS- 341 in patients with hematologic malignancies. Blood 2000;96:516.
-
(2000)
Blood
, vol.96
, pp. 516
-
-
Stinchcombe, T.E.1
Mitchell, B.S.2
Depcets-Smith, N.3
Orlowski, R.Z.4
Shea, T.C.5
Baldwin, A.S.6
-
58
-
-
27644590803
-
Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases
-
Katz H. Endodontic implications of bisphosphonate-associated osteonecrosis of the jaws: A report of three cases. J Endod 2005;31:831-4.
-
(2005)
J Endod
, vol.31
, pp. 831-4
-
-
Katz, H.1
-
59
-
-
12844260206
-
Recommendations for zoledronic acid treatment of patients with bone metastases
-
Berenson JR. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005;10:52-62.
-
(2005)
Oncologist
, vol.10
, pp. 52-62
-
-
Berenson, J.R.1
|